JP2009506978A - インスリン類の併用 - Google Patents

インスリン類の併用 Download PDF

Info

Publication number
JP2009506978A
JP2009506978A JP2008508028A JP2008508028A JP2009506978A JP 2009506978 A JP2009506978 A JP 2009506978A JP 2008508028 A JP2008508028 A JP 2008508028A JP 2008508028 A JP2008508028 A JP 2008508028A JP 2009506978 A JP2009506978 A JP 2009506978A
Authority
JP
Japan
Prior art keywords
insulin
phase
betaine
pharmaceutical
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506978A5 (https=
Inventor
メッサデク ジャアル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009506978A publication Critical patent/JP2009506978A/ja
Publication of JP2009506978A5 publication Critical patent/JP2009506978A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2008508028A 2005-04-27 2006-04-27 インスリン類の併用 Pending JP2009506978A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BEPCT/BE2005/000061 2005-04-27
PCT/BE2006/000040 WO2006113978A2 (en) 2005-04-27 2006-04-27 Insulins combinations

Publications (2)

Publication Number Publication Date
JP2009506978A true JP2009506978A (ja) 2009-02-19
JP2009506978A5 JP2009506978A5 (https=) 2009-06-18

Family

ID=37215100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508028A Pending JP2009506978A (ja) 2005-04-27 2006-04-27 インスリン類の併用

Country Status (10)

Country Link
US (1) US7786077B2 (https=)
EP (1) EP1885392B1 (https=)
JP (1) JP2009506978A (https=)
CN (1) CN101180073A (https=)
AT (1) ATE540690T1 (https=)
BR (1) BRPI0610249A2 (https=)
CA (1) CA2650556A1 (https=)
MX (1) MX2007013486A (https=)
RU (1) RU2007143510A (https=)
WO (1) WO2006113978A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525900A (ja) * 2008-06-26 2011-09-29 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 血糖制御のための新規グリシン酸メトホルミン塩

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DE602004003577T2 (de) * 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
WO2011094632A1 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation Method for administration of insulin and pharmaceutical composition thereof
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
WO2013021346A2 (en) * 2011-08-07 2013-02-14 Transgene Biotek Ltd A novel method for peroral delivery of insulin and its analogues for therapeutic usage
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3933845A3 (en) 2014-10-27 2022-06-22 Aseko, Inc. Subcutaneous outpatient management
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08133970A (ja) * 1994-11-11 1996-05-28 Nippon Beet Sugar Mfg Co Ltd 血糖値上昇抑制剤及び利用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2590M (fr) 1963-03-12 1964-06-15 Albert Beaufour Nouvelles associations antinévralgiques a tolérance améliorée.
US3577534A (en) 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
FR2119889A1 (en) 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
GB1509979A (en) 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
FR2403799A2 (fr) 1977-09-27 1979-04-20 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
US4605548A (en) 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
PL149493B1 (en) 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US4902718A (en) 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
EP0347864A3 (en) 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents
IT1226386B (it) 1988-07-08 1991-01-15 Chiesi Farma Spa Procedimento di preparazione di morniflumato e analoghi.
US4968719A (en) 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5405614A (en) 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
WO1995015750A1 (en) 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
US6355166B1 (en) 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US5961999A (en) 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
JP3119430B2 (ja) 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
US6162926A (en) 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
LV11727B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
AU2260397A (en) 1996-01-31 1997-08-22 Trustees Of The University Of Pennsylvania, The Remote control drug delivery device
US5880098A (en) 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
SE9601395D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP3174013B2 (ja) 1997-05-15 2001-06-11 コビシ電機株式会社 シール式センサ
US6258859B1 (en) 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
JP2002506024A (ja) 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
ATE311869T1 (de) 1998-10-30 2005-12-15 Merck Patent Gmbh Zubereitungen für die behandlung und verhinderung von kardiovaskulären erkrankungen
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
DE19910682B4 (de) 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
BE1012546A6 (fr) 1999-03-10 2000-12-05 Messadek Jallal La betaine et ses derives pour leur usage antithrombotique.
BE1012712A6 (fr) 1999-06-10 2001-02-06 Messadek Jallal Peptides antithrombotiques.
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
FR2811227A1 (fr) 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
EP1351686A2 (en) 2000-11-20 2003-10-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
JP2004515508A (ja) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
FI114538B (fi) 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
DK1408949T3 (da) 2001-02-05 2008-04-28 Jallal Messadek Glycinbetain og dets brugområde for opfindelsen
WO2002066002A2 (en) 2001-02-14 2002-08-29 Glaxo Wellcome S.A. Pharmaceutical formulation
US20040072750A1 (en) 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
WO2003020260A1 (en) 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
US20060160896A1 (en) 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
WO2004049095A2 (en) 2002-11-25 2004-06-10 Jallal Messadek Betaine and salicylic acid compositions
DE602004003577T2 (de) 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
US7097968B2 (en) 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
WO2005011645A2 (en) 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
US20060128657A1 (en) 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
EP1663174A1 (en) 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
BE1016128A6 (fr) 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08133970A (ja) * 1994-11-11 1996-05-28 Nippon Beet Sugar Mfg Co Ltd 血糖値上昇抑制剤及び利用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525900A (ja) * 2008-06-26 2011-09-29 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 血糖制御のための新規グリシン酸メトホルミン塩

Also Published As

Publication number Publication date
BRPI0610249A2 (pt) 2010-06-08
WO2006113978A2 (en) 2006-11-02
EP1885392B1 (en) 2012-01-11
US7786077B2 (en) 2010-08-31
RU2007143510A (ru) 2009-06-10
US20080214441A1 (en) 2008-09-04
EP1885392A2 (en) 2008-02-13
MX2007013486A (es) 2008-03-14
CA2650556A1 (en) 2006-11-02
ATE540690T1 (de) 2012-01-15
WO2006113978A3 (en) 2007-03-22
CN101180073A (zh) 2008-05-14

Similar Documents

Publication Publication Date Title
US7786077B2 (en) Insulins combinations
US7780990B2 (en) Combination therapeutic compositions and method of use
JP5000493B2 (ja) インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
US20130129815A1 (en) Liposomal formulation for oral administration of glutathione (reduced) via gel capsule
WO2012104834A1 (en) New oral dissolving films for insulin administration, for treating diabetes
IL182950A (en) Liposomal suspension for oral glutathione administration
EP1685833A1 (en) Remedy for diabetes
WO2020253835A1 (zh) 含有硝酸盐和维生素的组合物、其制备方法、制剂及其用途
US7943163B2 (en) Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
US20090054513A1 (en) Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
TW201705974A (zh) 第２型糖尿病病患治療
EP2651251A1 (en) Composition for the treatment of metabolic disorders
WO2006104401A1 (en) Copper antagonist compositions
CN101909604B (zh) 治疗血糖代谢障碍和葡萄糖漂移的方法
US20130108673A1 (en) Co-Therapy for Diabetic Conditions
TW201731506A (zh) 糖尿病治療劑之倂用
Quinn Pharmacologic management of the patient with type 2 diabetes
WO2009032591A1 (en) Food effect in treatment of diabetes with vanadium salts
WO2006033568A1 (es) Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades
HK1143067B (en) Pharmaceutical composition for treating dysglycemia and glucose excursions
TW201311270A (zh) 用於改善血糖控制作為基礎胰島素附加治療之醫藥組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120814